TRENDLINES: Fresh Capital, Including Lion Global's, Pours In Amid Efforts To Achieve Portfolio Windfalls

Two months, two fundraisings.

Investors have plonked down about S$9 million into The Trendlines Group in the past two months.

Lion Global Investors, a prominent institutional name, is said to have taken up the lion's share in the latest round.

Four other fundraisings (including two rights issues) were carried out in 2024 and 2025, bringing the aggregate to around S$25 million, since Haim Brosh became CEO in Nov 2023.

Aside from working capital, the proceeds were largely earmarked for follow-on investments in Trendlines' portfolio companies in order to retain the value created by its stars as they hit significant milestones.

The broker-initiated fundraisings reflect a vote of confidence in Trendlines' underlying portfolio -- and more specifically the singular "focus on exit" strategy of CEO Brosh.

HaimBrosh 12.2025 CEO Haim Brosh is focused on achieving exits for mature portfolio companies under Trendlines. The Israel- and Singapore-based investment group has over 40 medtech and agrifood start-ups, of which a number are mature enough for exits.

They have transformed from being early-stage technologies into potentially disruptive and viable businesses that some of the largest corporations are eager to own.

As a result, over the past two years, Trendlines' portfolio companies have collectively raised more than US$100 million from external investors.

Limaca Medical: A Case Study in Cutting-Edge MedTech

The strength of the Trendlines portfolio is evident in Limaca Medical, for example, which announced a milestone recently.

Founded in 2017, it said it had entered into an exclusive U.S. distribution agreement with a global leader in endoscopy equipment.

This partnership facilitates a nationwide rollout of the Precision-GI™ system, supported by FDA 510(k) clearance and CMS Transitional Pass-Through (TPT) payment status, which enables hospitals to claim reimbursements from insurers for the use of this device.

For decades, diagnosing gastrointestinal and pancreatic cancers has relied on manual needles.

These devices require a physician to manually "stab" a lesion up to 50 times to obtain samples.

This often results in fragmented, bloody specimens that are not easy for pathologists to analyze, frequently leading to inconclusive results and delayed treatment.

Limaca serves as a case study for the type of high-impact, disruptive technology that is driving investor interest in Trendlines.

Phytolon: Revolutionizing the Food Dye Industry

The US$4 billion global food dye market is at a crossroads.

Phytolon12.22 Phytolon produces colors through fermentation of baker's yeast to create betalain pigments.Consumers and regulators are rejecting synthetic dyes—often oil-derived subproducts—due to health concerns.

While the demand for natural colors is high, traditional plant-based extracts are often unsustainable and inconsistent.

Founded in 2018, Phytolon solves this through the "magic" of yeast fermentation.

Its process produces efficient, consistent, and sustainable natural pigments. This isn't just a lab experiment; Phytolon has already:

• Attracted the Giants: Several top-tier investors are strategically invested, including DSM, the world’s largest food ingredient company.

• Built for Scale: Outsourced production facilities are ready, and at least one key potential customer has done due diligence.

• The Next Milestone: Two years after its submission, Phytolon is awaiting the final word on FDA approval to begin commercial growth.

Looking Ahead

For Trendlines, these two portfolio companies' success stories reflect the potentially huge exits that will bring in long-awaited dividends for shareholders.

With institutional heavyweights like Lion Global Investors now on board and with sufficient capital, Trendlines is also equipped to nurture the next generation of of health and food innovators for future exits.